• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

David C. Fisher, MD


  • Watanabe R, Teague JE, Fisher DC, Kupper TS, Clark RA.Alemtuzumab Therapy for Leukemic Cutaneous T-Cell Lymphoma: Diffuse Erythema as a Positive Predictor of Complete Remission.JAMA Dermatol. 2014 Apr 23.
  • Mane M, O'Neill AC, Tirumani SH, Shi M, Shinagare AB, Fisher DC.Thyroid lymphoma on a background of Hashimoto's thyroiditis: PET/CT appearances.Clin Imaging. 2014 Mar 14.
  • Szabatura AH, Cirrone F, Harris C, McDonnell AM, Feng Y, Voit D, Neuberg D, Butrynski J, Fisher DC.An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.J Oncol Pharm Pract. 2014 Mar 24.
  • Chen MH, Blackington LH, Zhou J, Chu TF, Gauvreau K, Marcus KJ, Fisher DC, Diller LR, Ng AK.Blood pressure is associated with occult cardiovascular disease in prospectively studied Hodgkin lymphoma survivors after chest radiation.Leuk Lymphoma. 2014 Feb 27.
  • Nambudiri VE, Mutyambizi K, Walls AC, Fisher DC, Bleday R, Saavedra AP.Successful treatment of perianal giant condyloma acuminatum in an immunocompromised host with systemic interleukin 2 and topical cidofovir.JAMA Dermatol. 2013 Sep;149(9):1068-70.
  • Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS.Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma.British Journal of Haematology. 2013 Oct;163(1):123-6.
  • Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, Schlapbach C, Schaekel K, Rook AH, Tawa M, Fisher DC, Kupper TS, Clark RA.TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma.Clin Cancer Res. 2013 Jul 15;19(14):3755-63.
  • Brown JR, Messmer BT, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, Lacasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS.A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia / small lymphocytic lymphoma.Haematologica. 2013 May 3.
  • Ng AK, Garber JE, Diller LR, Birdwell RL, Feng Y, Neuberg DS, Silver B, Fisher DC, Marcus KJ, Mauch PM.Prospective Study of the Efficacy of Breast Magnetic Resonance Imaging and Mammographic Screening in Survivors of Hodgkin Lymphoma.J Clin Oncol. 2013 Apr 22.
  • Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen YB.Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era.British Journal of Haematology. 2013 Mar;160(5):608-17.
  • Abramson JS, Takvorian RW, Fisher DC, Feng Y, Jacobsen ED, Brown JR, Barnes JA, Neuberg DS, Hochberg EP.Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study.Leuk Lymphoma. 2013 Jan 30.
  • Barnes J, Jacobsen E, Feng Y, Freedman A, Hochberg E, Lacasce A, Armand P, Joyce R, Sohani A, Rodig S, Neuberg D, Fisher D, Abramson J.Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma.Haematologica. 2012 Nov 9.
  • Velez NF, Ishizawar RC, Dellaripa PF, Saavedra AP, Laga AC, Murphy GF, Fisher DC, Kupper TS, Vleugels RA.Full facial edema: a novel presentation of subcutaneous panniculitis-like T-cell lymphoma.J Clin Oncol. 2012 Sep 1;30(25):e233-6.
  • Parithivel K, Ramaiya N, Jagannathan JP, O'Regan K, Krajewski K, Fisher D, Choueiri TK, Jacobsen E.Everolimus- and Temsirolimus-Associated Enteritis: Report of Three Cases.J Clin Oncol. 2011 Feb 28.
  • Chen YB, Hochberg EP, Feng Y, Neuberg D, Rawal B, Motyckova G, Fisher DC, McAfee SL, Spitzer TR, Lacasce AS.Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone.Leuk Lymphoma. 2010 May;51(5):789-96.
  • Canellos GP, Abramson JS, Fisher DC, Lacasce AS.Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation Therapy.J Clin Oncol. 2010 Mar 20;28(9):1611-5.
  • Brown JR,Friedberg JW,Feng Y,Scofield S,Phillips K,Dal Cin P,Joyce R,Takvorian RW,Fisher DC,Fisher RI,Liesveld J,Marquis D,Neuberg D,Freedman AS.A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.British Journal of Haematology. 2009 Jun;145(6):741-8.
  • Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS.Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.British Journal of Haematology. 2009 Aug;146(3):282-91.
  • Luthy SK,Ng AK,Silver B,Degnan KO,Fisher DC,Freedman AS,Mauch PM.Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma.Ann Oncol. 2008 Dec;19(12):2043-7.
  • Armand P,Gannamaneni S,Kim HT,Cutler CS,Ho VT,Koreth J,Alyea EP,LaCasce AS,Jacobsen ED,Fisher DC,Brown JR,Canellos GP,Freedman AS,Soiffer RJ,Antin JH.Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.J Clin Oncol. 2008 Dec 10;26(35):5767-74.
  • Ng AK, Li S, Neuberg D, Chi R, Fisher DC, Silver B, Mauch PM.A prospective study of pulmonary function in Hodgkin's lymphoma patients.Ann Oncol. 2008 Oct;19(10):1754-8.
  • Brown JR,Neuberg D,Phillips K,Reynolds H,Silverstein J,Clark JC,Ash M,Thompson C,Fisher DC,Jacobsen E,LaCasce AS,Freedman AS.Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders.British Journal of Haematology. 2008 Nov;143(3):361-8.
  • Friedberg J, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher D, Szot A, Van Den Abbeele A, Freedman A.Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept.Leuk Lymphoma. 2008 May;49(5):902-9.
  • Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE.Major response to imatinib mesylate in KIT-mutated melanoma.J Clin Oncol. 2008 Apr 20;26(12):2046-51.
  • Drappatz J, Akar S, Fisher DC, Samuels MA, Kesari S.Imaging of Bing-Neel syndrome.Neurology. 2008 Apr 15;70(16):1364.
  • Fisher DE, Medrano EE, McMahon M, Soengas MS, Schuchter L, Wolchok JD, Merlino G.Meeting Report: Fourth International Congress of the Society for Melanoma Research.Pigment Cell Melanoma Res. 2008 Feb;21(1):15-26.
  • Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP.Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25.
  • Sato-Jin K, Nishimura EK, Akasaka E, Huber W, Nakano H, Miller A, Du J, Wu M, Hanada K, Sawamura D, Fisher DE, Imokawa G.Epistatic connections between microphthalmia-associated transcription factor and endothelin signaling in Waardenburg syndrome and other pigmentary disorders.FASEB J. 2008 Apr;22(4):1155-68.
  • Edwards CJ, Cooper C, Fisher D, Field M, van Staa TP, Arden NK.The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis.Arthritis Rheum. 2007 Oct 15;57(7):1151-7.
  • Widlund HR, Fisher DE.Potent p53-independent tumor suppressor activity of ARF in melanoma-genesis.Pigment Cell Res. 2007 Oct;20(5):339-40.
  • Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS.Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.Biol Blood Marrow Transplant. 2007 Sep;13(9):1057-65.
  • Kawakami A, Sakane F, Imai S, Yasuda S, Kai M, Kanoh H, Jin HY, Hirosaki K, Yamashita T, Fisher DE, Jimbow K.Rab7 regulates maturation of melanosomal matrix protein gp100/Pmel17/Silv.J Invest Dermatol. 2008 Jan;128(1):143-50.
  • Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, Dey BR, Attar E, McAfee S, Konopleva M, Antin JH, Spitzer TR.Phase I trial of parathyroid hormone to facilitate stem cell mobilization.Biol Blood Marrow Transplant. 2007 Jul;13(7):838-43.
  • Brown JR, Kim HT, Li S, Stephans K, Fisher DC, Cutler C, Ho V, Lee SJ, Milford EL, Ritz J, Antin JH, Soiffer RJ, Gribben JG, Alyea EP.Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.Biol Blood Marrow Transplant. 2006 Oct;12(10):1056-64.
  • Ng AK, Li S, Neuberg D, Fisher DC, McMillan C, Silver B, Marcus KC, Stevenson MA, Mauch PM.Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease.Ann Oncol. 2006 Nov;17(11):1693-7.
  • Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, Freedman AS, Mauch P, Schlossman R, Sequist LV, Soiffer RJ, Marshall B, Neuberg D, Ritz J, Nadler LM.Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.Blood. 2005 Dec 15;106(13):4389-96.
  • Ng AK, Bernardo MV, Silver B, Van Den Abbeele A, Stevenson MA, Fisher DC, Mauch PM.Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease.Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):175-84.
  • Lee SJ, Loberiza FR, Antin JH, Kirkpatrick T, Prokop L, Alyea EP, Cutler C, Ho VT, Richardson PG, Schlossman RL, Fisher DC, Logan B, Soiffer RJ.Routine screening for psychosocial distress following hematopoietic stem cell transplantation.Bone Marrow Transplant. 2005 Jan;35(1):77-83.
  • Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS.Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.Blood. 2005 Jan 15;105(2):489-95.
  • Lacasce A, Howard O, Lib S, Fisher D, Weng A, Neuberg D, Shipp M.Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity.Leuk Lymphoma. 2004 Apr;45(4):761-7.
  • Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, Fisher DC, Miklos D, Levin J, Sonis S, Soiffer RJ, Antin JH.Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.Biol Blood Marrow Transplant. 2004 May;10(5):328-36.
  • Brown JR, Gaudet G, Friedberg JW, Neuberg D, Mauch P, Kutok JL, Takvorian T, Fisher DC, Gribben JG, Kim H, Nadler LM, Freedman AS.Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma.Leuk Lymphoma. 2004 Feb;45(2):315-20.
  • Ng AK, Li S, Neuberg D, Silver B, Stevenson MA, Fisher DC, Mauch PM.Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease.Ann Oncol. 2004 Feb;15(2):270-5.
  • Friedberg JW, Dong DA, Li S, Kim H, Stephans K, Noonan K, Neuberg D, Gribben JG, Fisher DC, Freedman AS, Takvorian T, Jurgens R, Battle TE, Frank DA.Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.Leuk Res. 2004 Feb;28(2):139-47.
  • Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J, Freeman A, Parikh B, Richardson P, Soiffer R, Ritz J, Anderson KC.Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.Bone Marrow Transplant. 2003 Dec;32(12):1145-51.
  • Friedberg JW, Kim H, Li S, Neuberg D, Boyd K, Daley H, Fisher DC, Gribben JG, Spitzer T, Freedman AS.Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma.Bone Marrow Transplant. 2003 Oct;32(7):681-6.
  • Friedberg JW, Neuberg D, Kim H, Miyata S, McCauley M, Fisher DC, Takvorian T, Canellos GP.Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity.Cancer. 2003 Sep 1;98(5):978-82.
  • Alyea EP, Weller E, Fisher DC, Freedman AS, Gribben JG, Lee S, Schlossman RL, Stone RM, Friedberg J, DeAngelo D, Liney D, Windawi S, Ng A, Mauch P, Antin JH, Soiffer RJ.Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.Biol Blood Marrow Transplant. 2002;8(11):601-7.
  • Baksh S, Widlund HR, Frazer-Abel AA, Du J, Fosmire S, Fisher DE, DeCaprio JA, Modiano JF, Burakoff SJ.NFATc2-mediated repression of cyclin-dependent kinase 4 expression.Mol Cell. 2002 Nov;10(5):1071-81.
  • Webb IJ, Friedberg W, Gribben JG, Fisher DC, Spitzer T, Neuberg D, Jallow H, Kim H, Houde H, Monroy R, Schmittling R, Freedman AS.Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma.Biol Blood Marrow Transplant. 2002;8(8):429-34.
  • Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, Koval M, Poor CM, Green LM, Daley J, Soiffer R, Ritz J, Freedman AS.Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma.Br J Haematol. 2002 Jun;117(4):828-34.
  • Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, Mauch P, Marcus K, Fisher D, Freeman A, Parikh B, Gribben J, Soiffer R, Ritz J, Anderson K.T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.Blood. 2001 Aug 15;98(4):934-9.
  • Thorner AR, Travis AC, Hecht JL, Conrow DS, Fisher DC.Unusual presentations of malignancy. Case 3. Mantle-cell lymphoma of soft tissue.J Clin Oncol. 2001 Jul 1;19(13):3291-3.
  • Treon SP, Agus TB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC.CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.J Immunother. 2001 May-Jun;24(3):272-9.
  • Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL, Gribben J, Lee S, Anderson KC, Marcus K, Stone RM, Antin JH, Ritz J.CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors.J Clin Oncol. 2001 Feb 15;19(4):1152-9.
  • Backstrand KH, Ng AK, Takvorian RW, Jones EL, Fisher DC, Molnar-Griffin BJ, Silver B, Tarbell NJ, Mauch PM.Results of a prospective trial of mantle irradiation alone for selected patients with early-stage Hodgkin's disease.J Clin Oncol. 2001 Feb 1;19(3):736-41.
  • Lee SJ, Fairclough D, Parsons SK, Soiffer RJ, Fisher DC, Schlossman RL, Antin JH, Weeks JC.Recovery after stem-cell transplantation for hematologic diseases.J Clin Oncol. 2001 Jan 1;19(1):242-52.
  • Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, Schlossman R, Alyea EP, Takvorian T, Jallow H, Kuhlman C, Ritz J, Nadler LM, Gribben JG.Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma.Blood. 1999 Nov 15;94(10):3325-33.
  • Friedberg JW, Neuberg D, Gribben JG, Mauch P, Anderson KC, Soiffer RJ, Takvorian T, Fisher DC, Schlossman R, Jallow H, Kuhlman C, Ritz J, Freedman AS.Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies.Biol Blood Marrow Transplant. 1999;5(4):262-8.
  • Soiffer RJ, Freedman AS, Neuberg D, Fisher DC, Alyea EP, Gribben J, Schlossman RL, Bartlett-Pandite L, Kuhlman C, Murray C, Freeman A, Mauch P, Anderson KC, Nadler LM, Ritz J.CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.Bone Marrow Transplant. 1998 Jun;21(12):1177-81.
  • Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.Biol Blood Marrow Transplant. 1997 Apr;3(1):11-7.
  • Fisher DC, Sherrill GB, Hussein A, Rubin P, Vredenburgh JJ, Elkordy M, Ross M, Petros W, Peters WP.Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer.Bone Marrow Transplant. 1996 Jul;18(1):193-8.
  • Boyd AW, Tedder TF, Griffin JD, Freedman AS, Fisher DC, Daley J, Nadler LM.Preexposure of resting B cells to interferon-gamma enhances their proliferative response to subsequent activation signals.Cell Immunol. 1987 May;106(2):355-65.
  • Freedman AS, Boyd AW, Anderson KC, Fisher DC, Schlossman SF, Nadler LM.B5, a new B cell-restricted activation antigen.J Immunol. 1985 Apr;134(4):2228-35.
  • Boyd AW, Fisher DC, Fox DA, Schlossman SF, Nadler LM.Structural and functional characterization of IL 2 receptors on activated human B cells.J Immunol. 1985 Apr;134(4):2387-92.
  • Freedman AS, Boyd AW, Anderson KC, Fisher DC, Pinkus GS, Schlossman SF, Nadler LM.Immunologic heterogeneity of diffuse large cell lymphoma.Blood. 1985 Mar;65(3):630-7.
  • Anderson KC, Boyd AW, Fisher DC, Leslie D, Schlossman SF, Nadler LM.Hairy cell leukemia: a tumor of pre-plasma cells.Blood. 1985 Mar;65(3):620-9.
  • Boyd AW, Anderson KC, Freedman AS, Fisher DC, Slaughenhoupt B, Schlossman SF, Nadler LM.Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody.J Immunol. 1985 Mar;134(3):1516-23.
  • Anderson KC, Boyd AW, Fisher DC, Slaughenhoupt B, Groopman JE, O'Hara CJ, Daley JF, Schlossman SF, Nadler LM.Isolation and functional analysis of human B cell populations. I. Characterization of the B1+B2+ and B1+B2- subsets.J Immunol. 1985 Feb;134(2):820-7.